Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 10/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100770 | 0.95 | KCNN4 (0.37) | KCNN4KDRFYNALDH1A1NOS3 | |
| SCHEMBL10100585 | 0.88 | KCNN4 (0.44) | KCNN4FYNALDH1A1 | |
| SCHEMBL10100581 | 0.87 | MCHR1 (0.40) | KCNN4KDRGRIN1GRIN2BTLR7 | |
| SCHEMBL10100584 | 0.86 | FYN (0.41) | KCNN4FYNTLR7 | |
| SCHEMBL10100591 | 0.85 | SMN1; SMN2 (0.40) | KDR | |
| SCHEMBL10100542 | 0.85 | FYN (0.44) | KCNN4KDRFYNTLR7 | |
| SCHEMBL2358641 | 0.84 | KCNN4 (0.36) | KCNN4FYNTLR7 | |
| SCHEMBL10100771 | 0.84 | KCNN4 (0.43) | KCNN4FYNALDH1A1 | |
| SCHEMBL10100587 | 0.84 | FYN (0.42) | KCNN4FYNALDH1A1 | |
| SCHEMBL2358505 | 0.83 | LRRK2 (0.42) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | KCNN4 4066/4885KDR 213/4885FYN 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.